FierceBiotech13h
Charles River continues slide in Q3 as CEO spots reduced spending by biopharma clients
Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...
FierceBiotech16h
Boundless Bio drug shrinks tumors in mice by targeting extrachromosomal DNA
When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to ...
FierceBiotech18h
FDA clears its first treatment for dry AMD, with LumiThera’s light-based Valeda system
The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...
FierceBiotech19h
Acadia to make $100M profit from selling pediatric review voucher for $150M
Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will ...
FierceBiotech18h
Ring Therapeutics calls on Singapore research agencies for gene therapy R&D partnership
Ring Therapeutics is calling on Singaporean research agencies to dial into a new collaboration to develop gene therapies for eye diseases and cancer. | Ring Therapeutics is calling on Singaporean ...
FierceBiotech20h
Tango has last dance with PRMT5 inhibitor, pirouettes into embrace with 2 sibling molecules
Tumors outside the central nervous system (CNS) did respond but the failure to shrink brain tumors took away TNG908’s raison d'etre. Tango has another MTA-cooperative PRMT5 inhibitor, TNG462, for ...